Press Releases
Press Release filters
Sign up to receive updates from mdxhealth
Click the button below to fill in your contact information and receive updates from mdxhealth.
MDxHealth to Participate in Prospective 4M Clinical Study Evaluating Synergy of MRI and SelectMDx for Prostate Cancer
600 Patient Study to Evaluate Emerging Technologies for Improved Selection of Patients for Prostate Biopsy IRVINE, CA, and HERSTA
MDxHealth Launches SelectMDx “Liquid Biopsy” Test in Europe
Non-invasive, urine-based prostate cancer test available in the Netherlands from November 2015 IRVINE, CA, and HERSTAL, BELGIUM
MDxHealth Appoints Walter Narajowski as Independent Director
IRVINE, CA, and HERSTAL, BELGIUM – October 5, 2015 – MDxHealth SA (Euronext: MDXH.BR), today announces that it has strengthened it
MDxHealth (R): Completion of the acquisition of NovioGendix – New share capital amount and new number of shares
IRVINE, CA, and HERSTAL, BELGIUM – September 18, 2015 – MDxHealth SA (Euronext Brussels: MDXH) (the “Company”) announced today tha
MDxHealth’s ConfirmMDx Covered by Tufts Health Plan
IRVINE, CA, and HERSTAL, BELGIUM – September 17, 2015 – MDxHealth SA (Euronext: MDXH.BR) announced that it has signed an agreement
MDxHealth Acquires NovioGendix to Expand Uro-Oncology Product Offering
The acquisition gives MDxHealth access to a validated, non-invasive liquid biopsy test for prostate cancer in the US and EU Ur
MDxHealth Reports New ConfirmMDx Risk Score Data at 11th World Congress on Urological Research
Results demonstrate that patients can be stratified for low and highgrade prostate cancer IRVINE, CA, and HERSTAL, BELGIUM, Sept
MDxHealth Shareholder Transparency Notification
IRVINE, CA, and HERSTAL, BELGIUM, September 3, 2015 – 7:00 AM CET – MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic
MDxHealth Reports First Half 2015 Results
Revenues up 64% to $7.9 million ConfirmMDx revenue up 77% to $6.9 million Cash position strengthened with $31.0 million priv
MDxHealth Announces Positive Top-Line Data for its Liquid Biopsy Test for Bladder Cancer
Signs worldwide exclusive agreement with Erasmus MC for bladder cancer DNA methylation markers Full data to be presented at 11th
MDxHealth Appoints Philip J. Ginsburg M.D. as Chief Medical Officer
IRVINE, CA, and HERSTAL, BELGIUM, June 14, 2015 – MDxHealth SA (Euronext: MDXH), announced today, the appointment of Philip J. Gin
MDxHealth – Transparency declaration update
IRVINE, CA, and HERSTAL, BELGIUM, July 9, 2015 – MDxHealth SA (Euronext: MDXH) (the “Company”) announces, in accordance with artic
MDxHealth’s new share capital amount and new number of shares
IRVINE, CA, and HERSTAL, BELGIUM – June 26, 2015 – MDxHealth SA (Euronext Brussels: MDXH) announced today, in conformity with arti
MDxHealth Successfully Raises € 27.7 million (USD 31.0 million) In Equity Placement
THIS ANNOUNCEMENT IS NOT FOR Distribution, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, Sout
MDxHealth Launches Equity Placement
THIS ANNOUNCEMENT IS NOT FOR Distribution, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, Sout
MDxHealth Shareholder Transparency Notification
IRVINE, CA, and HERSTAL, BELGIUM, June 23, 2015 – MDxHealth SA (Euronext: MDXH), announced today that it received the following n
MDxHealth – Disclosure of the number of outstanding voting securities
IRVINE, CA, and HERSTAL, BELGIUM, June 8, 2015 – MDxHealth SA (Euronext: MDXH), announced today, pursuant to article 15 of the Bel
MDxHealth – Annual General Shareholders’ Meeting
IRVINE, CA, and HERSTAL, BELGIUM, May 29, 2015 -MDxHealth SA (Euronext: MDXH), held its Annual General Meeting of shareholders in
MDxHealth’s ConfirmMDx® Predicts Prostate Cancer Aggressiveness
Epigenetic Health Index Helps Urologists with Prognostic Recommendations
MDxHealth Provides First Quarter 2015 Business Update
ConfirmMDx Test Revenue Increases 177% over First Quarter 2014 IRVINE, CA, and HERSTAL, BELGIUM – May 5, 2015 – MDxHealth SA
